Search Result

Results for "

tumor growth and metastasis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	EGFR (1) Nuclear Hormone Receptor 4A/NR4A (1) VEGFR (4) Akt (1) Amino Acid Derivatives (1) AMPK (1) Antibiotic (1) Apoptosis (8) Aurora Kinase (1) Autophagy (1) Bacterial (1) Bcl-2 Family (2) c-Met/HGFR (1) Carbonic Anhydrase (1) CD73 (2) DNA/RNA Synthesis (2) Endogenous Metabolite (2) FAK (2) Fungal (2) FXR (1) Glycosyltransferase (1) HDAC (4) HIF/HIF Prolyl-Hydroxylase (1) Histone Methyltransferase (1) Integrin (1) Isotope-Labeled Compounds (1) Microtubule/Tubulin (2) Mitochondrial Metabolism (2) MMP (4) NF-κB (1) Parasite (1) Phosphatase (1) Phosphodiesterase (PDE) (1) PPAR (1) Ras (2) Reactive Oxygen Species (2) Src (2) STAT (2) TRP Channel (1) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (46) Cardiovascular Disease (1) Infection (3) Metabolic Disease (1) Neurological Disease (1)
Oligonucleotides:	Phospholipids (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: TNF Receptor FGFR BRK GHR VEGFR TGF-beta/Smad PDGFR TGF-β Receptor GHSR Fat Mass and Obesity-associated Protein (FTO) EGFR IGF-1R Nuclear Hormone Receptor 4A/NR4A

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-116399

MMP-2/MMP-9-IN-1	MMP	Cancer
MMP-2/MMP-9-IN-1 is a highly selective, orally active and potent type IV collagenase (MMP-9 and MMP-2) inhibitor with IC₅₀s of 0.24 and 0.31 μM for MMP-9 and MMP-2, respectively. MMP-2/MMP-9-IN-1 is orally active in animal models of tumor growth and metastasis. MMP-2/MMP-9-IN-1 can be used for the research of cancer .

HY-13648

Incyclinide 5+ Cited Publications CMT-3; COL-3	MMP	Cancer
Incyclinide (CMT-3, COL-3) is a matrix metalloproteinase (MMP) inhibitor and inhibiting angiogenesis, tumor growth and invasion, and metastasis.

HY-W088100

Boc-N-gamma-trityl-D-asparagin N-Boc-N'-trityl-D-asparagine; Boc-D-Asn(Trt)-OH	Amino Acid Derivatives	Cancer
Boc-N-gamma-trityl-D-asparagin (N-Boc-N'-trityl-D-asparagine) is an amino acid derivative with a Boc protecting group, which can be used to synthesize metastasis-inhibiting or tumor growth-inhibiting metastasis-inhibiting MS derivatives .

HY-16516

Vitamin CK3	Others	Cancer
Vitamin CK3 is the combination of Vitamin C and vitamin K3 (100:1 ratio) and has been shown to inhibit tumor growth and lung metastasis.

HY-P2452

Vitronectin (367-378)	Integrin	Cancer
Vitronectin (367-378) is a peptide corresponding to residues 367-378 of Vitronectin. Vitronectin is a multifunctional glycoprotein known in several human tumors for its adhesive role in processes such as cell growth, angiogenesis and metastasis .

HY-W021040

Fludioxonil CGA-173506	Fungal Apoptosis	Infection Cancer
Fludioxonil (CGA-173506) is a phenylpyrrole-type fungicide with oral activity that can inhibit the growth of S. sclerotiorum. Fludioxonil promotes tumor growth and metastasis, and induces cardiac toxicity. Fludioxonil causes cytoskeletal disruption, DNA damage, and apoptosis in mouse glioma cells .

HY-142965

HDAC-IN-28	HDAC	Cancer
HDAC-IN-28, a novel HDAC inhibitor, shows potent activities against tumor growth and metastasis

HY-13546

ABT-518	MMP	Cancer
ABT-518 is a matrix metalloproteinase inhibitor with anti-tumor activity. ABT-518 has potent inhibitory effects on gelatinase A and gelatinase B, which can inhibit tumor growth and metastasis .

HY-169520

VEGFR/PDGFR-IN-1	VEGFR	Cancer
VEGFR/PDGFR-IN-1 (Compound 1) is the inhibitor for VEGFR with an IC₅₀ of 0.4 μM. VEGFR/PDGFR-IN-1 inhibits angiogenesis in HUVEC cell, exhibiting potential in tumor growth and metastasis inhibition .

HY-120046

YF479	HDAC	Cancer
YF479 is a potent inhibitor of histone deacetylase. YF479 abates cell viability, suppresses colony formation and tumor cell motility. YF479 significantly inhibits breast tumor growth and metastasis. YF479 has the potential for the research of clinical trials for breast cancer .

HY-147594

CD73-IN-13	CD73	Cancer
CD73-IN-13 is a potent inhibitor of CD73. CD73 is closely associated with tumor growth, angiogenesis and metastasis. CD73-IN-13 be used for preparing a medicament for tumor-related diseases (extracted from patent CN114437039A, compound 7) .

HY-P10833

VGB3	VEGFR	Cardiovascular Disease Cancer
VGB3 is an antagonist peptide of vascular endothelial growth factor receptor 1 (VEGFR1)/VEGFR2 with antiangiogenic and antitumor effects. VGB3 binds to both VEGFR1 and VEGFR2, thereby inhibits VEGF-driven proliferation, migration and tube formation of endothelial cells, and tumor growth and metastasis in murine 4T1 mammary carcinoma tumor model .

HY-169084

ST-IN-1	Glycosyltransferase	Cancer
ST-IN-1 (compound (R)-1) is a selective ST inhibitor (K_i=70 nM, rat a-2,6-ST; K_i=19 nM, hST6GAL1) with antitumor activity. ST-IN-1 inhibits tumor growth and metastasis by delipidating the surface of tumor cells .

HY-155251

anti-TNBC agent-3	Apoptosis Bcl-2 Family	Cancer
anti-TNBC agent-3 (compound 3g) is an apoptosis inducer with anti-cancer cell proliferation activity. anti-TNBC agent-3 inhibits tumor growth and metastasis in triple-negative breast cancer (TNBC) xenograft models .

HY-10338A

Foretinib phosphate	c-Met/HGFR VEGFR	Cancer
Foretinib phosphate is an orally bioavailable small molecule with potential anti-tumor activity. Foretinib phosphate can selectively inhibit hepatocyte growth factor (HGF) receptor c-MET and vascular endothelial growth factor receptor 2 (VEGFR2), thereby potentially inhibiting tumor angiogenesis, tumor cell proliferation and metastasis. Foretinib phosphate shows different anti-cancer activity from cabozantinib in lung cancer cells and has stronger inhibitory effects on targets such as MEK1/2, FER and AURKB .

HY-107999

CADD522 4 Publications Verification	Reactive Oxygen Species	Cancer
CADD522 is a RUNX2-DNA binding inhibitor (downregulates RUNX2-mediated transcription of downstream target genes), with an IC₅₀ of 10 nM. CADD522 inhibits primary tumor growth and experimental metastasis of tumor cells in the lungs of immune-compromised mice. CADD522 can be used in study of cancer .

HY-100443

PX20606 PX-102	FXR	Cancer
PX20606 is an orally active agonist for farnesoid X receptor (FXR), with EC₅₀ 220 nM (mFXR) and 50 nM (hFXR), measured by Gal4-FXR assay. PX20606 induces the expression of tumor suppressor gene NDRG2, inhibits the tumor growth and metastasis in mouse HCC model. PX20606 exhibits hepatoprotective efficacy .

HY-121524

DJ101	Microtubule/Tubulin	Cancer
DJ101 is a potent and metabolically stable tubulin inhibitor. DJ101 targets the colchicine binding site and overcomes taxane resistance. DJ101 also inhibits melanoma tumor growth and lung metastasis. DJ101 can be used for prostate cancer research .

HY-16516R

Vitamin CK3 (Standard)	Reactive Oxygen Species Endogenous Metabolite	Cancer
Vitamin CK3 (Standard) is the analytical standard of Vitamin CK3. This product is intended for research and analytical applications. Vitamin CK3 is the combination of Vitamin C and vitamin K3 (100:1 ratio) and has been shown to inhibit tumor growth and lung metastasis.

HY-124875

Arylsulfonamide 64B HIF inhibitor 64B	HIF/HIF Prolyl-Hydroxylase	Neurological Disease
Arylsulfonamide 64B (HIF inhibitor 64B) is an inhibitor of the hypoxia-induced factor (HIF)*. Arylsulfonamide 64B inhibits hypoxia/HIF-induced expression of c-Met and CXCR4 and reduces primary tumor* growth and metastasis of uveal melanoma mouse model .**

HY-P10550

VGB4	VEGFR	Cancer
VGB4 is a VEGF-A and VEGF-B antagonist peptide that duplicates two binding domains of VEGF-B (loop 1 and loop3) and are linked together by the receptor-binding domain of VEGF-A (loop3). VGB4 has significant anti-angiogenic and anti-tumor activities and can regulate tumor growth and metastasis through multiple mechanisms. VGB4 could be used in anti-tumor research .

HY-155523

Tubulin/HDAC-IN-2	Microtubule/Tubulin HDAC Apoptosis	Cancer
Tubulin/HDAC-IN-2 (Compound II-19k) is a dual inhibitor of Tubulin and HDAC, with an IC₅₀ of 0.403 μM, 0.591μM, 3.552μM, 0.459μM for HDAC1/2/3/6. Tubulin/HDAC-IN-2 blocks cell cycle arrest at G2 phase, induces cell *apoptosis. Tubulin/HDAC-IN-2 inhibits the growth* of hematoma and solid tumor cells, reduces tumor metastasis, and also inhibits tumor growth in a liver tumor allograft mouse model .**

HY-158126

G-quadruplex ligand 2	DNA/RNA Synthesis	Cancer
G-quadruplex ligand 2 (compound A3) is a triphenylamine-based ligand that targets mitochondrial DNA G4s. G-quadruplex ligand 2 activates the cGAS-STING pathway. G-quadruplex ligand 2 inhibits tumor growth and metastasis via regulation of TME .

HY-120241

Reticulol K 251-1	Phosphodiesterase (PDE)	Cancer
Reticulol (K 251-1) is an inhibitor of cyclic adenosine 3', 5'-monophosphate phosphodiesterase. Reticulol shows antitumor activity independent with cell cycle arrest or apoptosis. Reticulol inhibits cell growth of murine melanoma cells and human lung tumor cells. Reticulol protects its lung metastasis via the bloodstream by inhibiting the growth of B16F10 melanoma .

HY-156483

TT-012	Others	Cancer
TT-012 specifically binds to dynamic MITF and destroys the latter's dimer formation and DNA-binding ability. TT-012 inhibits the transcriptional activity of MITF in B16F10 melanoma cells. TT-012 inhibits the growth of high-MITF melanoma cells, and inhibits the tumor growth and metastasis with tolerable toxicity to liver and immune cells in animal models .

HY-18959

CWP232228 5 Publications Verification	β-catenin Wnt	Cancer
CWP232228, a highly potent selective Wnt/β-catenin signaling inhibitor, antagonizes binding of β-catenin to T-cell factor (TCF) in the nucleus. CWP232228 suppresses tumor formation and metastasis without toxicity through the inhibition of the growth of breast and liver cancer stem cells (CSCs) .

HY-W021040S

Fludioxonil-13C3 CGA-173506-¹³C₃	Isotope-Labeled Compounds Fungal Apoptosis	Infection Cancer
Fludioxonil- ¹³C₃ (CGA-173506- ¹³C₃) is ¹³C labeled Fludioxonil. Fludioxonil (CGA-173506) is a phenylpyrrole-type fungicide with oral activity that can inhibit the growth of S. sclerotiorum. Fludioxonil promotes tumor growth and metastasis, and induces cardiac toxicity. Fludioxonil causes cytoskeletal disruption, DNA damage, and apoptosis in mouse glioma cells .

HY-121410

Narasin	Bacterial Apoptosis Parasite NF-κB Antibiotic	Infection Cancer
Narasin is a cationic ionophore antibiotic and coccidiostat agent. Narasin inhibits NF-κB signaling and induces tumor cells apoptosis. Narasin has antimicrobial, antiviral anticancer activity. Narasin inhibits tumor metastasis and growth of ERα‑positive breast cancer cells by inactivation of the TGF-β/SMAD3 and IL‑6/STAT3 signaling pathways .

HY-164546

WB436B	STAT Apoptosis	Cancer
WB436B is a highly selective STAT3 inhibitor. WB436B can selectively inhibit STAT3-Tyr705 phosphorylation and the expression of STAT3 target genes, showing cytotoxic effects on pancreatic cancer cells and inducing apoptosis. WB436B can suppress tumor growth and metastasis in pancreatic cancer mouse models, extending the survival of tumor-bearing mice .

HY-123130

ABT-770	MMP	Cancer
ABT-770 (compound 11) is a highly selective and orally active MMP inhibitor, demonstrating over 1000-fold selectivity for MMP-2 (IC₅₀=4 nM) compared to MMP-1 (IC₅₀=4600 nM). ABT-770 can be utilized in studies related to tumor growth, invasion, and metastasis .

HY-145426

MPT0B390	HDAC	Cancer
MPT0B390 is an arylsulfonamide-based derivative with potent HDAC inhibitory ability. MPT0B390, TIMP3 inducer, inhibits tumor growth, metastasis and angiogenesis. MPT0B390 shows antiproliferative activity against human colon cancer cell line HCT116 with the GI₅₀ of 0.03 μM .

HY-147593

CD73-IN-12	CD73	Cancer
CD73-IN-12 is a potent inhibitor of CD73. CD73 is closely associated with tumor growth, angiogenesis and metastasis. CD73-IN-12 be used for preparing a medicament for tumor-related diseases (extracted from patent CN114437038A, compound 9) . CD73-IN-12 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-13561

AZM475271 M475271	Src	Cancer
AZM475271 (M475271) is an orally active and selective Src kinase inhibitor. AZM475271 inhibits phosphorylation of c-Src kinase, Lck, c-yes (IC₅₀s = 0.01, 0.03, 0.0 8 μM, respectively). AZM475271 induces apoptosis. AZM475271 reduces tumor cell proliferation and migration in vitro an vivo, and reduces microvessel density (MVD). AZM475271 inhibits tumor growth and metastasis. AZM475271 sensitizes tumor cells to the cytotoxic effects of Gemcitabine (HY-17026) .

HY-143407

FAK-IN-3	FAK	Cancer
FAK-IN-3 (Compound 36) is a potent inhibitor of focal adhesion kinase (FAK). FAK-IN-3 not only decreases migration and invasion of PA-1 cells, but also reduces expression of MMP-2 and MMP-9. FAK-IN-3 inhibits tumor growth and metastasis, and no obvious adverse effects. FAK-IN-3 has the potential for the research of ovarian cancer .

HY-116804

ZLD1039	Histone Methyltransferase	Cancer
ZLD1039 is a potent, highly selective, and orally bioavailable EZH2 inhibitor. ZLD1039 shows potent and concentration-dependent inhibition of PRC2 enzymatic activity against EZH2 wild-type as well as Y641F, and A677G mutant enzymes with IC₅₀ values of 5.6, 15, and 4.0 nM, respectively. ZLD1039 inhibits breast tumor growth and metastasis .

HY-162879

FAK inhibitor 7	FAK Src Akt Autophagy	Cancer
FAK inhibitor 7 is a type of FAK inhibitor with an IC₅₀ value of 3.58 nM. FAK inhibitor 7 can inhibit the downstream signaling cascades of FAK (like Src and AKT), causing ovarian cancer cells to stall in the G0/G1 phase and induce cytotoxic autophagy. FAK inhibitor 7 can also suppress tumor metastasis and growth in ovarian cancer mice .

HY-110243

CAIX Inhibitor S4 1 Publications Verification	Carbonic Anhydrase	Cancer
CAIX Inhibitor S4 is a potent and selective inhibitor of carbonic anhydrase IX/XII (CA IX/XII), with a K_i of 7 nM and 2 nM, respectively. CAIX Inhibitor S4 also inhibits CA II and CA I (K_i=546 and 5600 nM, respectively). CAIX Inhibitor S4 can inhibit the number of lung metastasis in orthotopic MDA-MB-231 mouse model without affecting primary tumor growth .

HY-157480

EGFR/AURKB-IN-1	EGFR Aurora Kinase	Cancer
EGFR/AURKB-IN-1 (compound 7) is a dual-targeted EGFR/AURKB inhibitor, and inhibits the phpsphorylations of ^L858R EGFR and AURKB with IC₅₀s of 0.07 and 1.1, respectively. EGFR/AURKB-IN-1 occupies the hydrophobic region I or the αC-helix out pocket of EGFR and the back pocket of AURKB, inhibiting the growth, division and metastasis of tumor cells, thus can be used for cancer research .

HY-156077

anti-TNBC agent-2	Apoptosis DNA/RNA Synthesis	Cancer
anti-TNBC agent-2 (3j) an anti-Triple negative breast cancer (TNBC) purine derivative. anti-TNBC agent-2 induces MDA-MB-231 cells apoptosis, and inhibits its migration and angiogenesis. anti-TNBC agent-2 inhibits tumor growth and metastasis and reduces the expression of Ki67 and CD31 protein in TNBC xenograft models. anti-TNBC agent-2 can be used for Triple negative breast cancer (TNBC) research .

HY-12875

BQU57	Ras	Cancer
BQU57 is a selective inhibitor of RalA/RalB small GTPases, with a binding potency (Kb) of 7.7 μM for RalB-GDP. BQU57 can block its interaction with effector proteins (such as SEC5 and EXO84), inhibiting tumor cell migration, invasion and non-adherent growth. BQU57 downregulates the NF-κB signaling pathway, reduces the expression of IL-6, IL-8 and MMP-13, and inhibits apoptosis by regulating the Bcl-2/Bax balance. BQU57 also protects the extracellular matrix by inhibiting the Ral/NF-κB pathway and can be used for the study of degenerative diseases. BQU57 exhibits significant antitumor activity in triple-negative breast cancer (TNBC) models, inhibiting orthotopic tumor growth and lung metastasis and enhancing paclitaxel chemotherapy sensitivity .

HY-168012

Pan-RAS-IN-6	Ras Phosphatase	Cancer
Pan-RAS-IN-6 (compound 24) is an inhibitor targeting DUSP6, which reduces MAPK activation in the brain of the NCI-H1373-Luc model (DUSP6), at the same time, it shows significant tumor growth inhibition and tumor regression effects in the NSCLC brain metastasis mouse model. Pan-RAS-IN-6 shows high selectivity and strong inhibitory effects, especially in KRAS mutation-related signaling pathways, demonstrating varying inhibitory activity against different KRAS mutants and interacting proteins. The IC₅₀ values for KRAS G12C, G12D, and G12V are 1.3 nM, 4.7 nM, and 0.3 nM, respectively .

HY-P10873

ST-CY14	Nuclear Hormone Receptor 4A/NR4A Mitochondrial Metabolism	Cancer
ST-CY14 is an inhibitor for Nur77-PPARγ interaction with an EC₅₀ of 3.15 μM, that binds to Nur77 (K_d=32 nM), blocks Nur77 from being ubiquitinated and degraded by PPARγ, reduces fatty acid uptake and mitochondrial respiration, and inhibits the transcription of CD36 and FABP4. ST-CY14 inhibits the proliferation and migration of cancer cell MCF7 and MDA-MB-231. ST-CY14 inhibits tumor growth and bone metastasis in mouse models .

HY-118487A

OB-24 free base	Others	Cancer
OB-24 free base is a compound that potently and selectively inhibits heme oxygenase 1 (HO-1) and has the potential to inhibit advanced prostate cancer. OB-24 significantly reduces protein carbonylation and the formation of reactive oxygen species by selectively inhibiting HO-1 activity in prostate cancer cells. OB-24 significantly inhibited cell proliferation in vitro and inhibited tumor growth and lymph node and lung metastasis in vivo. OB-24 exhibits powerful synergy when used in combination with Taxol .

HY-N10612

Petasin	AMPK PPAR TRP Channel Mitochondrial Metabolism	Metabolic Disease Cancer
Petasin inhibits adipogenesis in cell 3T3-F442A with an IC₅₀ of 0.95 μM. Petasin inhibits the expression of lipid synthesis factors ACC1, FAS and SCD1 by inhibiting transcription factors PPARγ and C/EBPα, as well as targeting TRPA1 and TRPV1 channels . Petasin inhibits mitochondrial complex I, thereby inhibiting tumor growth and metastasis. Petasin activates AMPK signaling pathway, participating in regulation of glucose and lipid metabolism. Petasin is orally active .

HY-150603

STAT3-IN-13	STAT Apoptosis Bcl-2 Family	Cancer
STAT3-IN-13 (compound 6f) is a potent STAT3 inhibitor. STAT3-IN-13 has anti-proliferative effects and binds to the STAT3 SH2 domain with a K_D of 0.46 μM. STAT3-IN-13 inhibits the phosphorylation of STAT3 Y705 and downstream target gene expression. STAT3-IN-13 induces apoptosis in vitro and suppresses the growth and metastasis of tumor in vivo. STAT3-IN-13 can be used for cancer research .

HY-157693

C18:1 Cyclic LPA	Endogenous Metabolite	Cancer
C18:1 Cyclic LPA is a naturally occurring analog of the growth factor-like phospholipid mediator, lysophosphatidic acid (LPA), characterized by the formation of a 5-membered ring between its sn-2 hydroxy group and the sn-3 phosphate. This unique structure allows C18:1 Cyclic LPA to influence a variety of cellular functions, such as inhibiting cell cycle progression, promoting the formation of stress fibers, curtailing tumor cell invasiveness and metastasis, and modulating the differentiation and survival of neuronal cells. Notably, many of these cellular effects elicited by C18:1 Cyclic LPA appear to counter those induced by LPA, despite the activation of seemingly similar receptor populations.

Cat. No.	Product Name

HY-L135

Cancer Stem Cells Compound Library

2,615 compounds

With the progress of modern cancer therapy, the life of cancer patients has been extended. However, after initial treatment and recovery, the development of secondary tumors often leads to cancer recurrence. Cancer stem cells are a small number of cells that tumor growth and reproduction depend on.

Cancer stem cells have strong self-renewal ability, which is the direct cause of tumor occurrence. In addition, cancer stem cells also have the ability to differentiate into different cell types, playing a crucial role in tumor metastasis and development. Chemotherapy and radiotherapy induced DNA damage and apoptosis are common cancer treatments. However, cancer stem cells can effectively protect cancer cells from apoptosis by activating DNA repair ability. Cancer stem cells are regarded as the key "seed" of tumor occurrence, development, metastasis and recurrence. Since its first discovery in leukemia in 1994, cancer stem cells have been considered a promising therapeutic target for cancer treatment.

MCE supplies a unique collection of 2,615 compounds targeting key proteins in cancer stem cells. MCE Cancer Stem Cells Compound Library is a useful tool for cancer stem cells related research and anti-cancer drug development.

Cat. No.	Product Name	Target	Research Area